Fecal Microbiota Transplant with Pembrolizumab — Competitive Intelligence Brief

Fecal Microbiota Transplant with Pembrolizumab (Fecal Microbiota Transplant with Pembrolizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunotherapy. Area: Oncology.

phase 2 Immunotherapy PD-1/PD-L1 Oncology Small molecule

Target snapshot

Fecal Microbiota Transplant with Pembrolizumab (Fecal Microbiota Transplant with Pembrolizumab) — Zarour, Hassane, MD. Fecal microbiota transplant modulates the gut microbiome to stimulate an anti-tumor immune response through PD-1/PD-L1 pathway.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fecal Microbiota Transplant with Pembrolizumab TARGET	Fecal Microbiota Transplant with Pembrolizumab	Zarour, Hassane, MD	phase 2	Immunotherapy	PD-1/PD-L1
Pf-06865571	pf-06865571	Pfizer	marketed	Monoclonal antibody	PD-1/PD-L1 pathway
Pf-06823859	pf-06823859	Pfizer	marketed	Monoclonal Antibody	PD-1/PD-L1
Investigational products administration	Investigational products administration	Assistance Publique - Hôpitaux de Paris	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1
HyperAcute-Pancreas Immunotherapy	HyperAcute-Pancreas Immunotherapy	NewLink Genetics Corporation	phase 3	Cancer immunotherapy vaccine combination	Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway
SPARC1104 modified dose regimen I	SPARC1104 modified dose regimen I	Sun Pharma Advanced Research Company Limited	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1
TQB2303	TQB2303	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunotherapy class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. Beijing Tiantan Hospital · 1 drug in this class
3. CytoVac A/S · 1 drug in this class
4. Hannover Medical School · 1 drug in this class
5. Pfizer · 1 drug in this class
6. The Cleveland Clinic · 1 drug in this class
7. Zarour, Hassane, MD · 1 drug in this class